New Triple-Negative Breast Cancer Treatment
A new combination of drugs shows promise for stopping tumor growth in preclinical laboratory models.
Updated on Oct. 24, 2026 in Cancer
Researchers identified a promising combination therapy using BRD1 inhibitors and the drug carmofur to target triple-negative breast cancer cells. This approach aims to address the higher mortality rates associated with this aggressive cancer subtype.
Why it matters
Triple-negative breast cancer is known for being difficult to treat and having higher mortality rates than other types. By identifying how to enhance existing therapies like carmofur, scientists are working to improve outcomes for patients facing this aggressive condition.
A preclinical study identified that combining BRD1 inhibitors with the ASAH1 inhibitor carmofur resulted in more robust tumor growth inhibition compared to using either agent alone. The study, conducted in both cell cultures and in vivo models, remains preliminary.
The details
The treatment works by targeting ASAH1, an enzyme often overexpressed in these cancer cells. By combining the inhibitor carmofur with a BRD1 inhibitor like BAY-299, the researchers increased the activity of BCL6, a protein that acts as a transcriptional repressor. This cascade leads to the suppression of the BCL2 gene, which normally helps cancer cells avoid death, thereby triggering apoptosis or programmed cell death.
Timeline
October 24, 2026: The research findings were published.
Health Landscape
This study adds to the growing body of research exploring epigenetic regulators as a means to sensitize tumor cells to existing chemotherapy treatments. It sits within a wider effort to overcome drug resistance in aggressive breast cancer subtypes by targeting the biological pathways that prevent cell death.
This development is a preclinical finding and does not currently impact clinical care or treatment decisions for patients with breast cancer. Anyone diagnosed with breast cancer should speak with their oncology team about the standard-of-care treatments and ongoing clinical trials relevant to their specific diagnosis.
The takeaway
While preclinical research into new drug combinations offers hope for improving the treatment of aggressive breast cancers, it is important to remember that these results have not yet been validated in humans. Patients should continue to rely on established, physician-directed care and discuss any questions about emerging treatments with their specialist.
Further reading
Learn more about the latest research and treatment advancements in our Cancer section.
Source note: This article includes information reported by Nature.
